# Citations for Research Query

**Query:** # Mechanistic Hypothesis Search

You are evaluating a specific disease mechanism hypothesis for the Disorder
Mechanisms Knowledge Base. This is not a general disease overview. Use the
hypothesis YAML below as the seed claim, then search for evidence that supports,
refutes, qualifies, or competes with this hypothesis.

## Target Disease
- **Disease Name:** Hepatocellular Carcinoma
- **Category:**

## Target Hypothesis
- **Hypothesis ID:** rpp40_rnase_p_pretrna_mtor_myc_bridge
- **Hypothesis Label:** RNase P Pre-tRNA Processing as the RPP40-mTOR/MYC Bridge
- **Status in KB:** EMERGING

## Seed Hypothesis YAML

```yaml
hypothesis_group_id: rpp40_rnase_p_pretrna_mtor_myc_bridge
hypothesis_label: RNase P Pre-tRNA Processing as the RPP40-mTOR/MYC Bridge
status: EMERGING
description: Elevated RPP40 may sustain mTOR/MYC output in established hepatocellular carcinoma specifically
  because its contribution to RNase P preserves 5-prime pre-tRNA maturation and translational capacity.
  This narrow model predicts that an RNase P/pre-tRNA defect after acute RPP40 loss precedes signaling
  decline and is phenocopied by an RNase-P-specific perturbation. RPP40 is also shared with RNase MRP,
  however, and independent HCC evidence linking RPP40 to ribosomal-RNA and ribosomal-gene expression makes
  an RNase MRP/pre-rRNA or broader ribosome-biogenesis route a direct competitor. Neither published HCC
  study establishes the proposed RNase P ordering.
evidence:
- reference: PMID:42424930
  reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation
    by activating the mTOR/MYC signaling.
  supports: PARTIAL
  evidence_source: COMPUTATIONAL
  snippet: Analysis showed that RPP40 expression was markedly upregulated in HCC tissues compared to adjacent
    normal tissues. High RPP40 expression correlated with poorer clinical outcomes, even among patients
    with matched histological grade or pathological stage.
  explanation: Multi-dataset human-tumor associations support expression and prognostic correlation, but
    they do not establish whether RPP40 is a driver, dependency, or consequence of proliferative state.
- reference: PMID:42424930
  reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation
    by activating the mTOR/MYC signaling.
  supports: PARTIAL
  evidence_source: IN_VITRO
  snippet: RPP40 suppression attenuated cellular migration and proliferation, whereas its overexpression
    enhanced these malignant phenotypes both in vitro and in vivo.
  explanation: This item classifies the cell-culture component of the mixed result. The Huh-7 and HepG2
    perturbations support an RPP40-dependent malignant phenotype in vitro, but did not test pre-tRNA maturation
    or RNase-P specificity.
- reference: PMID:42424930
  reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation
    by activating the mTOR/MYC signaling.
  supports: PARTIAL
  evidence_source: MODEL_ORGANISM
  snippet: RPP40 suppression attenuated cellular migration and proliferation, whereas its overexpression
    enhanced these malignant phenotypes both in vitro and in vivo.
  explanation: This separately classifies the subcutaneous mouse-xenograft component of the mixed result.
    It supports an in-vivo model phenotype but neither human-tumor causality nor an RNase-P/pre-tRNA mechanism.
- reference: PMID:42424930
  reference_title: RPP40, a subunit of Ribonuclease P, facilitates hepatocellular carcinoma proliferation
    by activating the mTOR/MYC signaling.
  supports: PARTIAL
  evidence_source: COMPUTATIONAL
  snippet: The mTOR/MYC signaling pathway was pinpointed as the key pathway regulated by RPP40 in HCC.
  explanation: The integrated pathway analysis nominates mTOR/MYC downstream of RPP40, but the abstract
    does not establish the intervening RNA-processing branch.
notes: This hypothesis is intentionally not wired as a causal pathograph edge. Evidence supports the flanking
  RPP40 and mTOR/MYC observations, not the proposed RNase-P/pre-tRNA bridge.
```

## Research Objective

Build a focused hypothesis-search report that answers:

1. What is the strongest direct evidence for this hypothesis?
2. What evidence argues against it, fails to reproduce it, or limits its scope?
3. Which claims are established, emerging, speculative, or contradicted?
4. Which patient subtypes, stages, tissues, cell types, molecular pathways, or
   biomarkers does the hypothesis best explain?
5. Which alternative or competing mechanistic hypotheses explain the same disease
   features better or more parsimoniously?
6. What are the explicit knowledge gaps: missing causal steps, unconfirmed edges,
   contradictory evidence, unknown source-to-target links, or source/data absences?
7. What experiments, cohorts, assays, datasets, or trials would most directly
   distinguish this hypothesis from alternatives?

Use primary literature whenever possible. Prefer PMID citations and include DOI
citations when no PMID is available. Treat reviews as orientation unless they
contain directly relevant synthesized evidence that should be clearly labeled as
review-level support.

## Required Output

### Executive Judgment

Give a concise verdict on the hypothesis as of the current literature:
supported, partially supported, unresolved, weakly supported, or refuted. Explain
the reasoning and the most important caveats.

### Evidence Matrix

Create a table with one row per important evidence item:

- Citation (PMID preferred)
- Evidence type (human clinical, model organism, in vitro, computational, review)
- Supports / refutes / qualifies / competing
- Mechanistic claim tested
- Key finding
- Disease subtype or context
- Confidence and limitations

### Mechanistic Causal Chain

Describe the causal chain implied by the hypothesis from upstream trigger to
clinical manifestation. Identify where the literature is strong, where the links
are inferred, and where there are missing causal steps.

### Knowledge Gaps

Identify explicit known unknowns surfaced by the search. Treat absence of
evidence as a curation-relevant finding only when the search actually checked for
it. Include:

- Unknown or weakly supported causal steps in the hypothesis
- Unconfirmed causal graph edges that need direct perturbation or longitudinal
  evidence
- Conflicting evidence, failed replications, or incompatible subtype-specific
  findings
- Unknown mechanism of action for relevant treatments, biomarkers, or
  interventions tied to this hypothesis
- Source-level or dataset-level absences, such as no relevant GenCC, ClinGen,
  trial, omics, or cohort evidence found as of the search date

For each gap, state the scope, why it matters, what was checked, and what
evidence or experiment would resolve it.

### Alternative Models

List competing or complementary hypotheses. For each, explain whether it is an
alternative to the seed hypothesis, a downstream consequence, an upstream cause,
or a parallel mechanism.

### Discriminating Tests

Recommend concrete studies or assays that would most efficiently test this
hypothesis against alternatives. Include patient stratification, biomarkers,
sample type, model system, perturbation, and expected result where applicable.

### Curation Leads

Provide candidate updates for the KB, but label these as leads requiring curator
verification. Include:

- candidate evidence references and exact abstract snippets to verify
- candidate pathophysiology nodes or edges
- candidate ontology terms for cell types and biological processes
- candidate subtype restrictions or status changes
- candidate `knowledge_gaps` or discussion prompts for unresolved causal claims,
  conflicting evidence, or explicit source/data absences

If the provider supports artifacts, produce artifact-friendly outputs such as an
evidence matrix, mechanistic diagram, knowledge-gap table, or comparison table.
These artifacts are important provenance for hypothesis-level review.

**Provider:** openscientist
**Generated:** 2026-07-26T04:50:40.525995

1. PMID:42424930
2. PMID:16723659
3. PMID:25148809
4. PMID:41933259
5. PMID:36091104
6. PMID:37247644
7. PMID:37831743
8. PMID:29186115
9. PMID:42277007
10. PMID:35115551
11. PMID:41777667
12. PMID:18980784
13. PMID:28697848
14. PMID:39896489
15. PMID:36207533
16. PMID:36004921
17. PMID:40413743
18. PMID:40867056
19. PMID:22260684
20. PMID:42323524
21. PMID:41281472
22. PMID:35879647
23. PMID:25497380
24. PMID:35334008
25. PMID:36549864
26. PMID:39258975
27. PMID:33929081
